The Life Sciences Report | TalkMarkets | Page 2

The Life Sciences Report

Experience, Creativity And Dedication To Finding And Presenting The Best Investment Ideas
Contributor's Links: The Life Sciences Report
The Life Sciences Report features leading investment coverage of the life sciences sector, including biotechnology, pharmaceuticals, tools & diagnostics, and medical devices. A Streetwise Reports publication. The Streetwise Reports Team combines experience, creativity and dedication to ...more
Following: 17 Followers: 3026

All Contributions

Latest Posts
17 to 32 of 43 Posts
<<< 1 2 3 >>>
The 2016 Small-Cap Biotech Watchlist Debuts At The Biotech Showcase
Wednesday, January 27, 2016 6:16 PM EDT
This may prove a challenging year for small-cap biotechs, but the five analysts who selected companies for inclusion on The Life Sciences Report's 2016 Small-Cap Biotech Watchlist believe these companies have a good producing value for investors.
In this article: AZN, NVO, SGYP, SNY, CRMD, ORMP, CMXHY, SRNE, ALNY, ARRY, INCY, IRWD, PTIE, REGN, VRTX, AGEN, GALE, GRFS, PPHM, EVOK, ADMA, AKBA, VSTM, AST, RXDX, AGTC, NK, WVE, FATE, FLKS
Read
CAR T-Cell Therapeutics: Alan Leong Of BioWatch Looks Beyond The Buzz For Solid Early-Stage Plays
Wednesday, September 9, 2015 5:45 PM EDT
Alan Leong, senior analyst with BioWatch, tells us about the latest in CAR T-cell therapeutics and how some companies are hedging their bets by developing bispecific antibodies.
In this article: SRNE, DNDN, MDVN, SGEN, CELG, GILD, REPCF, JUNO, ADXS, KITE, BLUE, XON, CPXX, BLCM, NK
Read
Buy Biotech When There's Blood On The Street: Pontifax's Ran Nussbaum
Monday, September 7, 2015 8:00 AM EDT
Ran Nussbaum, managing partner with The Pontifax Group, doesn't worry too much about overall market volatility. Biotechs, he feels, are somewhat immune to turmoil because their fundamentals are based in real life.
In this article: AZN, BMY, JNJ, LLY, MRK, NVS, OPK, PFE, ALPMF, BAYRY, RHHBY, ARRY, BMRN, IMGN, MDVN, SGEN, CELG, CLVS, EXEL, GILD, TEVA, SAGE, MRNS, KITE, BLUE, FMI, ARNI
Read
Acquisitions Power Growth Of Companies And Portfolios: StoneCastle's Bruce Campbell
Thursday, August 20, 2015 1:52 PM EDT
Bruce Campbell of StoneCastle Investment Management describes five small-cap growth stories poised to ring up more acquisitions, more cash flow and more share price appreciation to portfolios.
In this article: CRMMF, PHMZF, HLTH, CVHIF Also: HCA, THC, VRX, AMSG, SCAI
Read
Harness Biotech Volatility With An Options Strategy: Theta Strategy Capital's Eden Rahim
Friday, August 14, 2015 4:13 AM EDT
Volatility is the nature of the biotech beast, and it must be tamed or utilized to advantage. That's the philosophy of Eden Rahim, portfolio manager and option strategist at Theta Strategies Capital.
In this article: ABT, AGN, SGYP, RPTP, MBXBF, PWCDF, RHHBY, SSDOY, ACAD, DNDN, FOLD, HALO, ILMN, MDVN, AMGN, BIIB, SHPG, REPCF, SUPN, BCLI, ITEK, RARE, PTLA, CPHR, PTGEF, BLUSF
Read
Regenerative Medicine In Japan: CJ Partners' Colin Lee Novick
Thursday, August 6, 2015 2:45 PM EDT
Colin Lee Novick, managing partner with CJ Partners, describes Japan's regenerative medicine frontier and lists investment-worthy companies that are pushing the boundaries.
In this article: AHKSY, ALPMF, BAYRY, CHGCF, FUJIY, LZAGF, NINOY, OTSKF, SGIOF, SSDOY, TKPYY, ATHX, REPCF
Read
Cantor Fitzgerald's Caroline Corner: Cutting-Edge Devices And Diagnostics Deliver Drugs And Profits
Tuesday, August 4, 2015 11:47 AM EDT
Caroline Corner of Cantor Fitzgerald follows companies with technologies that can both address dire diseases and reap windfalls for investors. Corner brings important names to investors' attention.
In this article: AGN, AEMD, CERS, D-STEM (DEFUNCT), NVIV, AERI, GKOS Also: RHHBY, ALIM, REGN, ONVO, XENT, MRK
Read
Four Small-Cap Medtechs Primed For Outsize Returns: Zacks' Brian Marckx
Thursday, July 16, 2015 8:05 AM EDT
In the U.S., the medical device and diagnostics industry has been burdened with conflicting regulations that have delayed commercialization and complicated reimbursement.
In this article: AEMD, CEMI, CTSO, ZMSPF Also: ALR, CODGF, OSUR
Read
Zacks' Jason Napodano Is Not Focused On A Biotech Bubble
Thursday, July 9, 2015 8:45 AM EDT
Jason Napodano, CFA, of Zacks Investment Research details the upside for small-cap biotech names that he believes will be huge gainers for investor portfolios.
In this article: BCLI, CUR, CYNAF, GSK, NVIV Also: NBI, ACOR, AMGN, BIIB, BLUE, CELG, DEPO, GILD, IBB, JUNO, KITE, LLY, MD, PFE, RVXCF, D-STEM (DEFUNCT), SYK
Read
Opportunities In Cancer Immunotherapy Throttle Up: George Zavoico Of JonesTrading
Friday, July 3, 2015 4:24 PM EDT
In this interview with The Life Sciences Report, Marcel Wijma, chief research analyst at Van Leeuwenhoeck Institute, explores some smaller companies working on the industry's forefront.
In this article: ABBV, EXAS, MXDHF, RVXCF, GLPGF Also: AZN, MBLTY, PFE, RHHBY
Read
Immuno-Oncology Promises Continued Wealth And Health: LifeTech Capital's Stephen Dunn
Monday, February 23, 2015 3:42 PM EDT
Immuno-oncology took center stage in the drug development world in 2014. But can this preeminence continue in 2015? In this interview, Stephen Dunn of LifeTech Capital outlines how companies are leveraging these therapies, and where investors should look for opportunity in the sector.
In this article: MRK, BMY, RHHBY, ESRX, PFE, MKGAY, AZN, KITE, JUNO, NVS, DNDN, JNJ, AMGN, XON, ZIOP, CBMG
Read
Capture Growth With Baskets Of Biotechs: LifeSci Advisors' Andrew McDonald
Friday, February 13, 2015 7:37 PM EDT
In this interview, Andrew McDonald describes how funds can be designed to grow on product sales and data generated via milestones in clinical development, and also names four companies he's included in the two portfolios.
In this article: GSK, CYTK, BBC, BBP, IBB, PCYC, JNJ, CELG, NVS, IDRA, PRTA, INFI, ABBV
Read
Bloom Burton's David Martin Zeroes In On Under-The-Radar Biotech
Thursday, February 12, 2015 5:59 PM EDT
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well.
In this article: NBI, BMY, MRK, RHHBY, ENDP, TRIL
Read
Convert Catalysts Into Profits: Sagient Research's Edward Stopke
Friday, January 23, 2015 5:48 PM EDT
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. Edward Stopke of Sagient Research unveils his list of companies with catalytic moments in the making.
In this article: PSTV, VCEL, ATHX, BLUE, CUR, KITE, NVS, AMGN, JUNO, RNN, MRK, ESALF, RPTP, CLDX, SRPT, PTCT, GILD, RMTI
Read
Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak
Friday, November 14, 2014 6:49 AM EDT
Mdtech analyst that has allowed the WBB Securities cofounder to develop a reasoned perspective on how West Africa's Ebola epidemic might be humanely halted. Brozak also mentions small-cap names that could considerably enhance investors' portfolios.
In this article: GSK, JNJ, NBS, BCRX, OMER, TKMR, CEMP, SRPT, CMRX, TTPH, NAVB
Read
ROTH Capital's Debjit Chattopadhyay: Marriage Of Diagnostics To New Therapies Breeds Biotech Winners
Wednesday, September 24, 2014 4:53 PM EDT
A medical researcher turned biotech analyst highlights several companies with unique diagnostic and therapeutic technologies.
In this article: BAX, CVD, DGX, NGNM, RHHBY, INCY, CTIC, RNA, SRPT
Read
17 to 32 of 43 Posts
<<< 1 2 3 >>>